No Data
Guangdong Hybribio Biotech (300639.SZ): has repurchased a cumulative 1.30% of shares.
On February 5, Gelonghui reported that Guangdong Hybribio Biotech (300639.SZ) announced that as of January 31, 2025, the company has cumulatively repurchased 8,394,525 shares, accounting for 1.30% of the company's current total share capital (excluding the shares in the company's special repurchase securities account); the highest Fill Price for the repurchase was 6.54 yuan/share, the lowest Fill Price was 5.54 yuan/share, and the total amount of funds paid was 49.67898 million yuan (including transaction fees).
Guangdong Hybribio Biotech (300639.SZ): Expected loss in 2024 is between 0.48 billion yuan to -0.68 billion yuan.
On January 24, Gelonghui reported that Guangdong Hybribio Biotech (300639.SZ) announced an expected loss of 480 million to -680 million yuan for 2024, with a non-recurring loss of 489.3 million to -689.3 million yuan. During the reporting period, the company continued to promote the global strategy of coordinated development among its three main business sectors: "molecular diagnostic products, medical testing services, and health management." Due to changes in industry demand and the inclusion of the company's key product HPV in centralized procurement, as well as large expenditures in its medical testing services business related to personnel benefits, depreciation, and leasing, the overall loss in the medical testing business sector was significant.
Capbio: 2024 Annual Results Forecast
Orient: DNA methylation assists in the diagnosis and treatment of endometrial cancer. Pay attention to companies related to the Industry Chain.
DNA methylation has been confirmed to have auxiliary diagnostic value for early endometrial cancer. With its advantages of being earlier and less invasive, it has become one of the methods for early auxiliary diagnosis of various cancers.
Further Weakness as Guangdong Hybribio BiotechLtd (SZSE:300639) Drops 9.9% This Week, Taking Three-year Losses to 57%
Guangdong Hybribio Biotech (300639.SZ): Has not yet begun the first buyback.
On December 2, Gelonhui | guangdong hybribio biotech (300639.SZ) announced that as of November 30, 2024, the company's third centralized competitive bidding method to repurchase company shares in 2024 has not yet begun the first repurchase.
